Report cover image

Global Transdermal Drug Delivery System Market Analysis and Forecast 2026-2032

Publisher APO Research, Inc.
Published Jan 09, 2026
Length 205 Pages
SKU # APRC20803488

Description

Transdermal Drug Delivery System is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. Often, this promotes healing to an injured area of the body. An advantage of a transdermal drug delivery route over other types of medication delivery such as oral, topical, intravenous, intramuscular, etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive.

Global Transdermal Drug Delivery System key players include Hisamitsu, Mylan, GSK, Novartis, Teve (Actavis), etc. Global top five manufacturers hold a share over 65%. North America is the largest market, with a share over 40%, followed by Europe and Asia-Pacific, both have a share over 45% percent.

In terms of product, Nitroglycerin is the largest segment, with a share over 25%. And in terms of application, the largest application is OTC, followed by RX.

Report Includes


This report presents an overview of global market for Transdermal Drug Delivery System, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Transdermal Drug Delivery System, also provides the revenue of main regions and countries. Of the upcoming market potential for Transdermal Drug Delivery System, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Transdermal Drug Delivery System revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Transdermal Drug Delivery System market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Transdermal Drug Delivery System revenue, projected growth trends, production technology, application and end-user industry.

Transdermal Drug Delivery System Segment by Company

Hisamitsu
Mylan
GSK
Novartis
Teve (Actavis)
Johnson & Johnson
Lohmann
Teikoku Seiyaku
Bayer
Lingrui
Sanofi
Qizheng
Endo
Huarun 999
Haw Par
Nichiban
Mentholatum
Laboratoires Genevrier

Transdermal Drug Delivery System Segment by Type

Fentanyl
Nitroglycerin
Estradiol
Nicotine
Other

Transdermal Drug Delivery System Segment by Application

OTC
Rx

Transdermal Drug Delivery System Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Transdermal Drug Delivery System market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Transdermal Drug Delivery System and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Transdermal Drug Delivery System.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline


Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Transdermal Drug Delivery System in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Transdermal Drug Delivery System company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Transdermal Drug Delivery System revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

205 Pages
1 Market Overview
1.1 Product Definition
1.2 Transdermal Drug Delivery System Market by Type
1.2.1 Global Transdermal Drug Delivery System Market Size by Type, 2021 VS 2025 VS 2032
1.2.2 Fentanyl
1.2.3 Nitroglycerin
1.2.4 Estradiol
1.2.5 Nicotine
1.2.6 Other
1.3 Transdermal Drug Delivery System Market by Application
1.3.1 Global Transdermal Drug Delivery System Market Size by Application, 2021 VS 2025 VS 2032
1.3.2 OTC
1.3.3 Rx
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Transdermal Drug Delivery System Market Dynamics
2.1 Transdermal Drug Delivery System Industry Trends
2.2 Transdermal Drug Delivery System Industry Drivers
2.3 Transdermal Drug Delivery System Industry Opportunities and Challenges
2.4 Transdermal Drug Delivery System Industry Restraints
3 Global Growth Perspective
3.1 Global Transdermal Drug Delivery System Market Perspective (2021-2032)
3.2 Global Transdermal Drug Delivery System Growth Trends by Region
3.2.1 Global Transdermal Drug Delivery System Market Size by Region: 2021 VS 2025 VS 2032
3.2.2 Global Transdermal Drug Delivery System Market Size by Region (2021-2026)
3.2.3 Global Transdermal Drug Delivery System Market Size by Region (2027-2032)
4 Competitive Landscape by Players
4.1 Global Transdermal Drug Delivery System Revenue by Players
4.1.1 Global Transdermal Drug Delivery System Revenue by Players (2021-2026)
4.1.2 Global Transdermal Drug Delivery System Revenue Market Share by Players (2021-2026)
4.1.3 Global Transdermal Drug Delivery System Players Revenue Share Top 10 and Top 5 in 2025
4.2 Global Transdermal Drug Delivery System Key Players Ranking, 2024 VS 2025 VS 2026
4.3 Global Transdermal Drug Delivery System Key Players Headquarters & Area Served
4.4 Global Transdermal Drug Delivery System Players, Product Type & Application
4.5 Global Transdermal Drug Delivery System Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Transdermal Drug Delivery System Market CR5 and HHI
4.6.3 2025 Transdermal Drug Delivery System Tier 1, Tier 2, and Tier 3
5 Transdermal Drug Delivery System Market Size by Type
5.1 Global Transdermal Drug Delivery System Revenue by Type (2021 VS 2025 VS 2032)
5.2 Global Transdermal Drug Delivery System Revenue by Type (2021-2032)
5.3 Global Transdermal Drug Delivery System Revenue Market Share by Type (2021-2032)
6 Transdermal Drug Delivery System Market Size by Application
6.1 Global Transdermal Drug Delivery System Revenue by Application (2021 VS 2025 VS 2032)
6.2 Global Transdermal Drug Delivery System Revenue by Application (2021-2032)
6.3 Global Transdermal Drug Delivery System Revenue Market Share by Application (2021-2032)
7 Company Profiles
7.1 Hisamitsu
7.1.1 Hisamitsu Company Information
7.1.2 Hisamitsu Business Overview
7.1.3 Hisamitsu Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
7.1.4 Hisamitsu Transdermal Drug Delivery System Product Portfolio
7.1.5 Hisamitsu Recent Developments
7.2 Mylan
7.2.1 Mylan Company Information
7.2.2 Mylan Business Overview
7.2.3 Mylan Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
7.2.4 Mylan Transdermal Drug Delivery System Product Portfolio
7.2.5 Mylan Recent Developments
7.3 GSK
7.3.1 GSK Company Information
7.3.2 GSK Business Overview
7.3.3 GSK Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
7.3.4 GSK Transdermal Drug Delivery System Product Portfolio
7.3.5 GSK Recent Developments
7.4 Novartis
7.4.1 Novartis Company Information
7.4.2 Novartis Business Overview
7.4.3 Novartis Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
7.4.4 Novartis Transdermal Drug Delivery System Product Portfolio
7.4.5 Novartis Recent Developments
7.5 Teve (Actavis)
7.5.1 Teve (Actavis) Company Information
7.5.2 Teve (Actavis) Business Overview
7.5.3 Teve (Actavis) Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
7.5.4 Teve (Actavis) Transdermal Drug Delivery System Product Portfolio
7.5.5 Teve (Actavis) Recent Developments
7.6 Johnson & Johnson
7.6.1 Johnson & Johnson Company Information
7.6.2 Johnson & Johnson Business Overview
7.6.3 Johnson & Johnson Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
7.6.4 Johnson & Johnson Transdermal Drug Delivery System Product Portfolio
7.6.5 Johnson & Johnson Recent Developments
7.7 Lohmann
7.7.1 Lohmann Company Information
7.7.2 Lohmann Business Overview
7.7.3 Lohmann Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
7.7.4 Lohmann Transdermal Drug Delivery System Product Portfolio
7.7.5 Lohmann Recent Developments
7.8 Teikoku Seiyaku
7.8.1 Teikoku Seiyaku Company Information
7.8.2 Teikoku Seiyaku Business Overview
7.8.3 Teikoku Seiyaku Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
7.8.4 Teikoku Seiyaku Transdermal Drug Delivery System Product Portfolio
7.8.5 Teikoku Seiyaku Recent Developments
7.9 Bayer
7.9.1 Bayer Company Information
7.9.2 Bayer Business Overview
7.9.3 Bayer Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
7.9.4 Bayer Transdermal Drug Delivery System Product Portfolio
7.9.5 Bayer Recent Developments
7.10 Lingrui
7.10.1 Lingrui Company Information
7.10.2 Lingrui Business Overview
7.10.3 Lingrui Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
7.10.4 Lingrui Transdermal Drug Delivery System Product Portfolio
7.10.5 Lingrui Recent Developments
7.11 Sanofi
7.11.1 Sanofi Company Information
7.11.2 Sanofi Business Overview
7.11.3 Sanofi Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
7.11.4 Sanofi Transdermal Drug Delivery System Product Portfolio
7.11.5 Sanofi Recent Developments
7.12 Qizheng
7.12.1 Qizheng Company Information
7.12.2 Qizheng Business Overview
7.12.3 Qizheng Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
7.12.4 Qizheng Transdermal Drug Delivery System Product Portfolio
7.12.5 Qizheng Recent Developments
7.13 Endo
7.13.1 Endo Company Information
7.13.2 Endo Business Overview
7.13.3 Endo Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
7.13.4 Endo Transdermal Drug Delivery System Product Portfolio
7.13.5 Endo Recent Developments
7.14 Huarun 999
7.14.1 Huarun 999 Company Information
7.14.2 Huarun 999 Business Overview
7.14.3 Huarun 999 Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
7.14.4 Huarun 999 Transdermal Drug Delivery System Product Portfolio
7.14.5 Huarun 999 Recent Developments
7.15 Haw Par
7.15.1 Haw Par Company Information
7.15.2 Haw Par Business Overview
7.15.3 Haw Par Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
7.15.4 Haw Par Transdermal Drug Delivery System Product Portfolio
7.15.5 Haw Par Recent Developments
7.16 Nichiban
7.16.1 Nichiban Company Information
7.16.2 Nichiban Business Overview
7.16.3 Nichiban Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
7.16.4 Nichiban Transdermal Drug Delivery System Product Portfolio
7.16.5 Nichiban Recent Developments
7.17 Mentholatum
7.17.1 Mentholatum Company Information
7.17.2 Mentholatum Business Overview
7.17.3 Mentholatum Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
7.17.4 Mentholatum Transdermal Drug Delivery System Product Portfolio
7.17.5 Mentholatum Recent Developments
7.18 Laboratoires Genevrier
7.18.1 Laboratoires Genevrier Company Information
7.18.2 Laboratoires Genevrier Business Overview
7.18.3 Laboratoires Genevrier Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
7.18.4 Laboratoires Genevrier Transdermal Drug Delivery System Product Portfolio
7.18.5 Laboratoires Genevrier Recent Developments
8 North America
8.1 North America Transdermal Drug Delivery System Revenue (2021-2032)
8.2 North America Transdermal Drug Delivery System Revenue by Type (2021-2032)
8.2.1 North America Transdermal Drug Delivery System Revenue by Type (2021-2026)
8.2.2 North America Transdermal Drug Delivery System Revenue by Type (2027-2032)
8.3 North America Transdermal Drug Delivery System Revenue Share by Type (2021-2032)
8.4 North America Transdermal Drug Delivery System Revenue by Application (2021-2032)
8.4.1 North America Transdermal Drug Delivery System Revenue by Application (2021-2026)
8.4.2 North America Transdermal Drug Delivery System Revenue by Application (2027-2032)
8.5 North America Transdermal Drug Delivery System Revenue Share by Application (2021-2032)
8.6 North America Transdermal Drug Delivery System Revenue by Country
8.6.1 North America Transdermal Drug Delivery System Revenue by Country (2021 VS 2025 VS 2032)
8.6.2 North America Transdermal Drug Delivery System Revenue by Country (2021-2026)
8.6.3 North America Transdermal Drug Delivery System Revenue by Country (2027-2032)
8.6.4 United States
8.6.5 Canada
8.6.6 Mexico
9 Europe
9.1 Europe Transdermal Drug Delivery System Revenue (2021-2032)
9.2 Europe Transdermal Drug Delivery System Revenue by Type (2021-2032)
9.2.1 Europe Transdermal Drug Delivery System Revenue by Type (2021-2026)
9.2.2 Europe Transdermal Drug Delivery System Revenue by Type (2027-2032)
9.3 Europe Transdermal Drug Delivery System Revenue Share by Type (2021-2032)
9.4 Europe Transdermal Drug Delivery System Revenue by Application (2021-2032)
9.4.1 Europe Transdermal Drug Delivery System Revenue by Application (2021-2026)
9.4.2 Europe Transdermal Drug Delivery System Revenue by Application (2027-2032)
9.5 Europe Transdermal Drug Delivery System Revenue Share by Application (2021-2032)
9.6 Europe Transdermal Drug Delivery System Revenue by Country
9.6.1 Europe Transdermal Drug Delivery System Revenue by Country (2021 VS 2025 VS 2032)
9.6.2 Europe Transdermal Drug Delivery System Revenue by Country (2021-2026)
9.6.3 Europe Transdermal Drug Delivery System Revenue by Country (2027-2032)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
9.6.9 Spain
9.6.10 Netherlands
9.6.11 Switzerland
9.6.12 Sweden
9.6.13 Poland
10 China
10.1 China Transdermal Drug Delivery System Revenue (2021-2032)
10.2 China Transdermal Drug Delivery System Revenue by Type (2021-2032)
10.2.1 China Transdermal Drug Delivery System Revenue by Type (2021-2026)
10.2.2 China Transdermal Drug Delivery System Revenue by Type (2027-2032)
10.3 China Transdermal Drug Delivery System Revenue Share by Type (2021-2032)
10.4 China Transdermal Drug Delivery System Revenue by Application (2021-2032)
10.4.1 China Transdermal Drug Delivery System Revenue by Application (2021-2026)
10.4.2 China Transdermal Drug Delivery System Revenue by Application (2027-2032)
10.5 China Transdermal Drug Delivery System Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
11.1 Asia Transdermal Drug Delivery System Revenue (2021-2032)
11.2 Asia Transdermal Drug Delivery System Revenue by Type (2021-2032)
11.2.1 Asia Transdermal Drug Delivery System Revenue by Type (2021-2026)
11.2.2 Asia Transdermal Drug Delivery System Revenue by Type (2027-2032)
11.3 Asia Transdermal Drug Delivery System Revenue Share by Type (2021-2032)
11.4 Asia Transdermal Drug Delivery System Revenue by Application (2021-2032)
11.4.1 Asia Transdermal Drug Delivery System Revenue by Application (2021-2026)
11.4.2 Asia Transdermal Drug Delivery System Revenue by Application (2027-2032)
11.5 Asia Transdermal Drug Delivery System Revenue Share by Application (2021-2032)
11.6 Asia Transdermal Drug Delivery System Revenue by Country
11.6.1 Asia Transdermal Drug Delivery System Revenue by Country (2021 VS 2025 VS 2032)
11.6.2 Asia Transdermal Drug Delivery System Revenue by Country (2021-2026)
11.6.3 Asia Transdermal Drug Delivery System Revenue by Country (2027-2032)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Transdermal Drug Delivery System Revenue (2021-2032)
12.2 SAMEA Transdermal Drug Delivery System Revenue by Type (2021-2032)
12.2.1 SAMEA Transdermal Drug Delivery System Revenue by Type (2021-2026)
12.2.2 SAMEA Transdermal Drug Delivery System Revenue by Type (2027-2032)
12.3 SAMEA Transdermal Drug Delivery System Revenue Share by Type (2021-2032)
12.4 SAMEA Transdermal Drug Delivery System Revenue by Application (2021-2032)
12.4.1 SAMEA Transdermal Drug Delivery System Revenue by Application (2021-2026)
12.4.2 SAMEA Transdermal Drug Delivery System Revenue by Application (2027-2032)
12.5 SAMEA Transdermal Drug Delivery System Revenue Share by Application (2021-2032)
12.6 SAMEA Transdermal Drug Delivery System Revenue by Country
12.6.1 SAMEA Transdermal Drug Delivery System Revenue by Country (2021 VS 2025 VS 2032)
12.6.2 SAMEA Transdermal Drug Delivery System Revenue by Country (2021-2026)
12.6.3 SAMEA Transdermal Drug Delivery System Revenue by Country (2027-2032)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.